

The Route from Development to Deployment of M-CELS for Drug Development

Kimberly A. Homan

Sr. Director and Distinguished Scientist, Genentech Inc.

Novel in vitro models can impact pharma in two ways: influencing internal decision-making (validating targets, optimizing lead candidate molecules, running mechanistic studies, etc) or supporting regulatory filings. The vast majority of uses occur in the internal decision-making space where often the studies aren't made public for proprietary reasons. This talk will provide a glimpse into how drug developers in pharma use models for internal decision-making and the critical characteristics (e.g. model-omics data) necessary for successful integration of new models into existing preclinical drug development pipelines. Further, examples will be highlighted which have reached regulatory filings. Looking to the future, pharma needs a robust suite of tools to truly deploy these models and realize their potential; challenges like scale and incorporation of human diversity are just some aspects we challenge the field to tackle to help meet the needs of patients.